A novel agent exerts antitumor activity in breast cancer cells by targeting mitochondrial complex II
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2744 views | HTML 3870 views | ?
Liang Wang1,*, Xiaojing Zhang2,*, Guozhen Cui1, Judy Yuet-Wa Chan1, Li Wang3, Chuwen Li1, Luchen Shan2, Changjiang Xu2, Qingwen Zhang1, Yuqiang Wang2, Lijun Di3, Simon Ming-Yuen Lee1
1State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China
2Institute of New Drug Research, College of Pharmacy, Jinan University, Guangzhou, China
3Faculty of Health Sciences, University of Macau, Macao, China
*These authors contributed equally to this work
Simon Ming-Yuen Lee, email: [email protected]
Lijun Di, email: [email protected]
Keywords: danshensu, tetramethylpyrazine, breast cancer, mitochondrial complex II, reactive oxygen species
Received: December 28, 2015 Accepted: March 02, 2016 Published: March 27, 2016
The mitochondrial respiratory chain, including mitochondrial complex II, has emerged as a potential target for cancer therapy. In the present study, a novel conjugate of danshensu (DSS) and tetramethylpyrazine (TMP), DT-010, was synthesized. Our results showed that DT-010 is more potent than its parental compounds separately or in combination, in inhibiting the proliferation of MCF-7 and MDA-MB-231 cells by inducing cytotoxicity and promoting cell cycle arrest. It also inhibited the growth of 4T1 breast cancer cells in vivo. DT-010 suppressed the fundamental parameters of mitochondrial function in MCF-7 cells, including basal respiration, ATP turnover, maximal respiration. Treatment with DT-010 in MCF-7 and MDA-MB-231 cells resulted in the loss of mitochondrial membrane potential and decreased ATP production. DT-010 also promoted ROS generation, while treatment with ROS scavenger, NAC (N-acetyl-L-cysteine), reversed DT-010-induced cytotoxicity. Further study showed that DT-010 suppressed succinate-induced mitochondrial respiration and impaired mitochondrial complex II enzyme activity indicating that DT-010 may inhibit mitochondrial complex II. Overall, our results suggested that the antitumor activity of DT-010 is associated with inhibition of mitochondrial complex II, which triggers ROS generation and mitochondrial dysfunction in breast cancer cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.